Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

336.43 +6.84 (+2.08%)
Streaming Delayed Price Updated: 11:30 AM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
Via Investor Brand Network
The Next Generation of the GLP-1 Revolution Is Already Underway
Via Investor Brand Network
News headline image
2 Dividend Stocks to Double Up On Right Now ↗
They can weather many storms. 
Via The Motley Fool
Topics Intellectual Property
Amgen Inc (NASDAQ:AMGN) Q1 Earnings Beat on EPS but Revenue Miss Sends Shares Lower ↗
Via Chartmill
Topics Earnings
News headline image
The Next Generation of the GLP-1 Revolution Is Already Underway
From BioMedWire
Via GlobeNewswire
News headline image
5 Must-Read Analyst Questions From Amgen’s Q1 Earnings Call
Amgen’s first quarter results reflected the company’s ability to outpace the impact of ongoing patent expirations and increased competition. Management credi... 
Via StockStory
Topics Earnings Intellectual Property
News headline image
2 Healthcare Stocks on Our Watchlist and 1 That Underwhelm
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in t... 
Via StockStory
News headline image
2 Nasdaq 100 Stocks with Competitive Advantages and 1 We Question
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win... 
Via StockStory
These S&P500 stocks are moving in today's session ↗
Via Chartmill
News headline image
Why the S&P 500 and Nasdaq Hit Record Highs While the Dow Fell Today ↗
Same market, different outcomes. Here's why Apple sent two indexes to record highs while the Dow slipped. 
Via The Motley Fool
Topics Government Stocks World Trade
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Friday's session: gap up and gap down stock in the S&P500 index ↗
Via Chartmill
What's going on in today's pre-market session: S&P500 movers ↗
Via Chartmill
News headline image
AMGN Q1 Deep Dive: Growth Drivers Offset Patent Losses, Pipeline Progress in Focus
Biotech company Amgen (NASDAQ:AMGN) announced better-than-expected revenue in Q1 CY2026, with sales up 5.8% year on year to $8.62 billion. The company expect... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Amgen (AMGN) Q1 2026 Earnings Transcript ↗
Amgen (AMGN) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Amgen’s (NASDAQ:AMGN) Q1 CY2026 Sales Top Estimates
Biotech company Amgen (NASDAQ:AMGN) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 5.8% year on year to $8.62 billion.... 
Via StockStory
Topics Intellectual Property
News headline image
EDMP picks up Sonoco, and the position size is doing the talking ↗
Sonoco Products Company delivers packaging solutions to global consumer and industrial markets, with a reported dividend yield of 4.2%. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings To Watch: Amgen (AMGN) Reports Q1 Results Tomorrow
Biotech company Amgen (NASDAQ:AMGN) will be announcing earnings results this Thursday afternoon. Here’s what investors should know. Amgen beat analysts’ reve... 
Via StockStory
News headline image
2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
3 Catalysts That Could Send Teva Stock to $40 and Beyond ↗
This once-beaten-down pharma stock remains an intriguing turnaround story. 
Via The Motley Fool
News headline image
2 S&P 500 Stocks Worth Your Attention and 1 We Ignore
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch... 
Via StockStory
Topics Stocks
News headline image
2 Dow Jones Stocks with Exciting Potential and 1 Facing Headwinds
While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising c... 
Via StockStory
Topics Stocks
News headline image
2 Reasons to Like AMGN and 1 to Stay Skeptical
Amgen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 14.8%. The stock now trades at $350.73, marking a 18% gain.... 
Via StockStory
Topics Stocks
News headline image
MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat
In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Johnson & Johnson Shatters Expectations in Q1 2026, Raising Full-Year Outlook as Healthcare Giant Pushes Toward $100 Billion Milestone
NEW BRUNSWICK, N.J. — In a powerful display of resilience and strategic execution, Johnson & Johnson (NYSE: JNJ) reported first-quarter 2026 financial results that exceeded Wall Street estimates across... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)
As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc.... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Amgen’s Subcutaneous TEPEZZA Data Sets New Gold Standard for Thyroid Eye Disease Treatment
THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its... 
Via MarketMinute
News headline image
The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026
As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Amgen Reclaims the Lead in Thyroid Eye Disease with Superior Subcutaneous TEPEZZA Data
In a major victory for its rare disease portfolio, Amgen (NASDAQ: AMGN) announced positive topline results on April 6, 2026, from its pivotal Phase 3 clinical trial evaluating a subcutaneous (SC)... 
Via MarketMinute
Topics Intellectual Property
News headline image
The "Daily Pill" Revolution: Eli Lilly’s Orforglipron Shatters Records with 25% Weight Loss
In a watershed moment for the pharmaceutical industry, Eli Lilly and Company (NYSE: LLY) has officially crossed the threshold into a new era of metabolic medicine. Freshly released data from the... 
Via MarketMinute
< Previous 1 2 3 4 5 6 7 8 9
...
65 66 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.